The FDA has approved the Daytrana patch, a skin patch for the treatment of ADHD (Attention Deficit Hyperactivity Disorder) in children. Regulators said the patch would help in the administration of ADHD drugs to children who find it hard to take pills or tablets. According to many experts, a large number of children taking ADHD medication have problems with swallowing pills.

The Daytrana Patch is a once-daily treatment for children 6-12. It should be placed on the skin (hip) early in the morning and removed nine hours later. The patch should be applied, alternately, on the left and right sides of the hip (e.g. Monday – left, Tuesday – right, etc.) The patch comes in four strengths.

The Daytrana patch is made by Shire Pharmaceuticals Group Plc (UK) and Noven Pharmaceuticals Inc (USA). The Daytrana Patch delivers the active ingredient of Ritalin (methylphenidate) via the skin. Ritalin is currently the most popular ADHD drug in the USA.

Label warnings will be the same as for other ADHD drugs concerning children who have existing heart conditions. Many would like to see more warnings on ADHD drugs. The Daytrana Patch will also carry warnings related to skin sensitivity – redness and bumps. Other possible side-effects include insomnia, weight loss, nausea/vomiting and anorexia.

The FDA stressed that the Daytrana Patch should be used as part of a comprehensive treatment program for ADHD, including educational and social elements.

Written by: Christian Nordqvist
Editor: Medical News Today